CVS Reports Lowest Drug Trend in Years
May 28
CVS Health Corp.’s 2019 drug trend report shows a 1.4% overall trend, the lowest in five years, and said 41% of its commercial clients saw negative trend. Specialty drugs accounted for almost half of all spending and remained the fastest growing spending category in the pharmacy benefit. Autoimmune treatments, including some of the highest volume medications — Humira, Enbrel, Rituxan and Remicade — comprised a third of specialty pharmacy spending. CVS’s Advanced Control Specialty Formulary (ACSF) helped its clients reach -9.4% price growth in the category. As 20 biosimilars are expected to come to the specialty marketplace by 2023, payers may see significant savings, according to CVS.
© 2023 MMIT
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
